These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9234664)

  • 1. KRN4884, a novel K channel opener: antihypertensive effects in conscious renal hypertensive dogs.
    Kawahara J; Jinno Y; Endo M; Izumi H; Takeuchi A; Izawa T
    J Cardiovasc Pharmacol; 1997 Jun; 29(6):814-9. PubMed ID: 9234664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
    Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive properties of KRN4884, a novel long-lasting potassium channel opener.
    Kawahara J; Kashiwabara T; Ogawa N; Okada Y; Izawa T
    J Cardiovasc Pharmacol; 1999 Feb; 33(2):292-4. PubMed ID: 10028939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of KRN4884 (a novel K+ channel opener), levcromakalim, nilvadipine and propranolol on endothelin-1-induced heart disorders in anesthetized rats.
    Harada K; Kawahara J; Okada Y; Uzumaki H; Kusaka M; Tokiwa T
    Jpn J Pharmacol; 1998 Nov; 78(3):261-8. PubMed ID: 9869259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the potassium channel openers KRN4884 and levcromakalim on the contraction of rat aorta induced by A23187, compared with nifedipine.
    Kawahara J; Izumi H; Okada Y; Izawa T
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):460-5. PubMed ID: 8897449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
    Nakajima T; Shinohara T; Yaoka O; Fukunari A; Shinagawa K; Aoki K; Katoh A; Yamanaka T; Setoguchi M; Tahara T
    J Pharmacol Exp Ther; 1992 May; 261(2):730-6. PubMed ID: 1578381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs.
    Shibasaki K; Takizawa K; Uchida W; Takenaka T
    Jpn J Pharmacol; 1997 Feb; 73(2):113-24. PubMed ID: 9074945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
    Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
    J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
    Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
    Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs.
    Kusumoto K; Awane Y; Kitayoshi T; Fujiwara S; Hashiguchi S; Terashita Z; Shiraishi M; Watanabe T
    J Cardiovasc Pharmacol; 1994 Dec; 24(6):929-36. PubMed ID: 7898076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo vasodilating effects of KRN4884, Ki1769 and Ki3005, pyridinecarboxamidine derivatives.
    Izumi H; Kawahara J; Takeuchi A; Izawa T; Ogawa N
    Fundam Clin Pharmacol; 1997; 11(6):561-6. PubMed ID: 9444524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nisoldipine (BAY K 5552), a new calcium antagonist. Antihypertensive effect in conscious, unrestrained renal hypertensive dogs.
    Knorr A
    Arch Int Pharmacodyn Ther; 1982 Nov; 260(1):141-50. PubMed ID: 7165419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
    Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of KRN4884, a novel K+ channel opener, on ionic currents in rabbit femoral arterial myocytes.
    Muraki K; Sasaoka A; Ohya S; Watanabe M; Imaizumi Y
    J Pharmacol Sci; 2003 Nov; 93(3):289-98. PubMed ID: 14646246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
    Paciorek PM; Burden DT; Burke YM; Cowlrick IS; Perkins RS; Taylor JC; Waterfall JF
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):188-97. PubMed ID: 1689412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models.
    Buckingham RE; Clapham JC; Hamilton TC; Longman SD; Norton J; Poyser RH
    J Cardiovasc Pharmacol; 1986; 8(4):798-804. PubMed ID: 2427821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antihypertensive property of NIP-121, a novel potassium channel opener in rats.
    Masuda Y; Arakawa C; Yokoyama T; Shigenobu K; Tanaka S
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):190-7. PubMed ID: 1717778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
    Kanda A; Haruno A; Miyake H; Nagasaka M
    J Cardiovasc Pharmacol; 1992; 20(5):723-30. PubMed ID: 1280733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effect of the new dihydropyridine calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in dogs.
    Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T
    Arzneimittelforschung; 1992 Apr; 42(4):513-8. PubMed ID: 1642675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.